Stay updated on Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    No significant changes detected on the Study Details page. The content and layout continue to present the trial design, eligibility, outcomes, and locations as before.
    Difference
    0.1%
    Check dated 2026-02-18T07:21:25.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Minor site maintenance updates were made: Revision: v3.4.2 was added and Revision: v3.4.1 was removed, along with a government operating status notice. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-11T09:17:16.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a site-wide notice about possible delays due to a lapse in government funding with links to cc.nih.gov and opm.gov for status updates. Updated the site to revision v3.4.1, replacing v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T05:22:31.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary feature and introduced the new Study Record Dates field 'Last Update Submitted that Met QC Criteria'. Standardized 'No FEAR Act' labeling and updated the page revision to v3.4.0.
    Difference
    0.2%
    Check dated 2026-01-28T03:43:28.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    - The page displays a new Revision: v3.3.4, replacing Revision: v3.3.3. There are no visible changes to study design, outcomes, eligibility, or listed locations.
    Difference
    0.1%
    Check dated 2026-01-14T01:17:53.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    A Locations section now includes North Carolina (Durham, NC) for the study, replacing the former 'North Carolina Locations' entry. The HHS Vulnerability Disclosure link was removed from the footer, and the page revision updated from v3.3.2 to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T20:54:31.000Z thumbnail image

Stay in the know with updates to Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.